Valuation: Nexstim Oyj

Market Cap 79.94M 91.48M 73.9M 68.28M 129M 8.79B 131M 881M 346M 4.3B 344M 336M 14.81B P/E 2026 *
82.5x
P/E 2027 * 36.7x
Enterprise Value 77.84M 89.07M 71.96M 66.48M 125M 8.56B 127M 858M 337M 4.19B 335M 327M 14.43B EV / Sales 2026 *
6.13x
EV / Sales 2027 * 4.74x
Free-Float
58.2%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 49 10/02/2020
Director of Finance/CFO 40 10/02/2020
Chief Tech/Sci/R&D Officer 65 31/12/2007
Director TitleAgeSince
Director/Board Member 64 10/11/2019
Chairman 63 10/11/2019
Director/Board Member 55 30/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
-6.90%-5.73% - - 87.37M
+1.05%+3.38%+25.56%+0.89% 196B
-6.78%-11.19%-26.52%+7.20% 144B
-0.55%+2.50%+0.66%-17.25% 142B
-4.52%-5.89%-59.14%-19.61% 66.37B
-1.85%-4.99%+15.09%-3.52% 52.85B
-3.57%-2.72%-25.44%-33.65% 45.22B
+0.87%+3.10%+12.59%+12.90% 37.86B
+0.85%+0.39%+23.74%+39.01% 36.64B
-5.59%-4.98%-17.18%-24.64% 29.71B
Average -2.15%-2.03%-5.63%-4.30% 83.43B
Weighted average by Cap. -1.53%-1.27%-2.86%-4.07%

Financials

2026 *2027 *
Net sales 12.7M 14.53M 11.74M 10.85M 20.43M 1.4B 20.8M 140M 54.93M 684M 54.59M 53.38M 2.35B 16.1M 18.42M 14.88M 13.75M 25.89M 1.77B 26.36M 177M 69.64M 867M 69.2M 67.67M 2.98B
Net income 1M 1.14M 924K 854K 1.61M 110M 1.64M 11.02M 4.33M 53.82M 4.3M 4.2M 185M 2.2M 2.52M 2.03M 1.88M 3.54M 242M 3.6M 24.25M 9.52M 118M 9.46M 9.25M 408M
Net Debt -2.1M -2.4M -1.94M -1.79M -3.38M -231M -3.44M -23.15M -9.08M -113M -9.03M -8.83M -389M -3.7M -4.23M -3.42M -3.16M -5.95M -407M -6.06M -40.79M -16M -199M -15.9M -15.55M -686M
Logo Nexstim Oyj
Nexstim Oyj is a Finland-based medical technology company. It is focused on improving rehabilitation for stroke patients through the use of noninvasive brain stimulation. Its offering comprises: a diagnostic tool for brain surgery planning, Navigated Brain Stimulation (NBS) System, which comprises navigated transcranial magnetic stimulation (nTMS) device for presurgical mapping (PSM) of the motor and speech cortices; and a device for stroke therapy called Navigated Brain Therapy (NBT) System, which focuses stimulation on targeted locations in the brain in order to enhance rehabilitation process. The NBT System targets upper limb motor disability and is under Phase III pivotal clinical trial study at rehabilitation sites in the United States. The Company’s systems are used in over 100 facilities in research, therapy and neurosurgical planning purposes. Nexstim Oyj has two subsidiaries: Nexstim Inc and Nexstim Germany GmbH.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-